Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
A phase 2 trial of Obinutuzumab, Glofitamab, Pirtobrutinib and clonoSEQ in Mantle cell lymphoma, run by University of California, San Francisco, now recruiting.
Overview
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma is a phase 2 interventional study registered as NCT06252675 by University of California, San Francisco, with 30 participants planned, started 2024-06-11 and due to reach its primary completion in 2028-07-31. Interventions recorded: Obinutuzumab, Glofitamab, Pirtobrutinib, Tumor Imaging, Biospecimen Collection, ClonoSeq Assay, Bone Marrow Biopsy. Conditions recorded: Mantle Cell Lymphoma.
Linked to the drug clonoSEQ because the registry names it among its interventions and Mantle cell lymphoma among its conditions. Registry record only: no result has been read by an editor.
Similar pages
not linked directly; found by shared links- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Glofitamab, Obinutuzumab, Mantle cell lymphoma and the tag pipeline.
- TrialMeasurable Residual Disease-Guided Post-Transplant Elranatamab Maintenance
Shares clonoSEQ and the tag pipeline.
- TrialStudy of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
Shares Pirtobrutinib, Mantle cell lymphoma and the tag pipeline.
- TrialA Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Shares Glofitamab, Obinutuzumab and the tag pipeline.
- TrialEvaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
Shares Glofitamab, Obinutuzumab and the tag pipeline.
- TrialA Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP
Shares clonoSEQ and the tag pipeline.
- TrialAn Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Shares Glofitamab, Obinutuzumab and the tag pipeline.
- TrialA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Shares Pirtobrutinib and the tag pipeline.